

Document 1069

[21069001]

Genentech Inc. said third-quarter profit more than doubled to \$ 11.4 million , or 13 cents a share . from a depressed 1988 third-quarter performance of \$ 5.3 million , or six cents a share .

[21069002]

Revenue rose 23 % to \$ 100 million from \$ 81.6 million .

[21069003]

Net product sales accounted for \$ 76 million , up from \$ 57.5 million a year earlier .

[21069004]

Sales of the heart drug TPA were \$ 43.6 million , better than last year 's depressed third period when the company sold just \$ 29.1 million of the drug .

[21069005]

But TPA sales fell below levels for this year 's first and second quarter sales of \$ 48 million , cooling investors .

[21069006]

Genentech stock fell 12.5 cents in trading yesterday on the New York Stock Exchange to \$ 20.125 .

[21069007]

In the nine months , net income slid 21 % to \$ 28.4 million , or 33 cents a share , from \$ 36 million , or 42 cents a share .

[21069008]

Revenues climbed 18 % to \$ 289 million from \$ 245.3 million .

[21069009]

" We continue to be on target for ... increasing TPA sales 20 % to 25 % this year , " said founder and Chief Executive Officer Robert Swanson .

[21069010]

But some analysts remain sour on the company .

[21069011]

" TPA sales are down quarter to quarter .

[21069012]

Expenses are flat and that 's a good sign .

[21069013]

There 's contract revenue from { limited research and development } partnerships .

[21069014]

